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Transcriptional profiling was performed on 452 RNA preparations isolated from various types of pancreatic tissue from tumour
patients and healthy donors, with a particular focus on peritumoral samples. Pancreatic ductal adenocarcinomas (PDAC) and
cystic tumours were most different in these non-tumorous tissues surrounding them, whereas the actual tumours exhibited
rather similar transcript patterns. The environment of cystic tumours was transcriptionally nearly identical to normal pancreas
tissue. In contrast, the tissue around PDAC behaved a lot like the tumour, indicating some kind of field defect, while showing
far less molecular resemblance to both chronic pancreatitis and healthy tissue. This suggests that the major pathogenic differ-
ence between cystic and ductal tumours may be due to their cellular environment rather than the few variations between the
tumours. Lack of correlation between DNA methylation and transcript levels makes it unlikely that the observed field defect in
the peritumoral tissue of PDAC is controlled to a large extent by such epigenetic regulation. Functionally, a strikingly large
number of autophagy-related transcripts was changed in both PDAC and its peritumoral tissue, but not in other pancreatic
tumours. A transcription signature of 15 autophagy-related genes was established that permits a prognosis of survival with
high accuracy and indicates the role of autophagy in tumour biology.
Pancreatic cancer is one of the most aggressive tumours at
all. Despite an incidence that represents only 3% of all cancer
cases in industrialised countries, it is the fourth most
common cause of tumour-related deaths in the Western
world.1,2 Pancreatic ductal adenocarcinoma (PDAC) is
accounting for >90% of cases and has the worst prognosis;
the other tumour types are less lethal. Most PDAC patients
die within a year of diagnosis; the overall 5-year survival rate
is about 5%. There is currently no efﬁcient treatment avail-
able except surgery, which can only be applied to 10% to
20% of cases, however.3 For an improvement of the clinical
situation, prognostic markers are required that allow predict-
ing clinical progression more accurately.4 Several studies on
RNA expression in pancreatic cancer have been performed
(http://www.pancreasexpression.org/cgi-bin/pancexp/DataSets.
pl). Substantial variations have been recorded between differ-
ent studies, documenting technical variance as well as tumour
heterogeneity. Several of these studies dealt with relatively
few RNA samples and material from one hospital source
only. In addition, only relatively few data are available on
pancreatic tumour types other than PDAC. The same is true
for non-tumorous pancreatic tissues and especially so for
peritumoral samples. A molecular differentiation of these tis-
sue entities and a detailed understanding of their relation to
the actual tumours are missing.
In order to provide a reliable source of information at sev-
eral molecular levels on a large set of tumour and control
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samples—including tissue samples that were close to tumour
but not part of it—we performed extensive analyses on origi-
nally >1,000 pancreatic tissue samples collected by surgery at
three major European pancreas clinics. At the DNA level,
results on the mutational status of the KRAS and CDKN2A
genes and their prognostic signiﬁcance have been reported,
for example.5 Furthermore, suitability of microRNA varia-
tions and DNA methylation for diagnosis has been studied6–8
and followed up by detailed investigations of their functional
contributions to the disease9 and the identiﬁcation of novel
routes for therapy.10
Here, we report about an analysis of transcriptional varia-
tions at the mRNA level performed on the basis of this
large dataset. We identiﬁed signiﬁcant variations between the
various tumour forms, but also detected unexpected similari-
ties between mRNA expression patterns. Particularly striking
was a substantial degree of similarity in transcriptional regu-
lation between PDAC and the surrounding peritumoral cel-
lular environment, indicating some kind of ﬁeld defect.
Interestingly, the transcriptional variation did not much
coincide with changes in the DNA-methylation levels, which
have been implicated in ﬁeld defects.11,12 Comparing cystic
tumours and PDAC, most transcriptional differences took
actually place in this peritumoral environment, while the
transcriptional patterns in the tumour tissues were rather
similar, suggesting an involvement of the wider cellular envi-
ronment of a tumour in its pathology. Looking at the data
from a functional angle, we inferred relevant pathways and
possible functional consequences. Our ﬁndings highlight
the importance of autophagy-related transcript expression in
the peritumoral environment of pancreatic tumours and
the potential role of autophagy-related genes for prognosis
and as legitimate targets for therapeutic intervention schemes.
Material and Methods
Tissue samples and histopathology
Human pancreatic tissue samples were collected during sur-
gery. In all cases, written informed consent was obtained
from the patients. The study was approved by the local ethics
committees at the universities of Heidelberg, Verona and Liv-
erpool. All “normal” samples were healthy pancreas tissues of
donors, who had no pancreatic disease. The samples were
snap-frozen in liquid nitrogen directly after resection and
subsequently stored at 2808C. All samples were analysed at
DKFZ following identical procedures. The frozen tissue was
cut into slices of 15 mm thicknesses with a Leica CM 1850
UV cryotome at 2348C; three slices were picked from the
top, middle and bottom third of a tumour and used for his-
topathology. All remaining slices were mixed to assure equal
representation of the entire tissue sample and split into three
aliquots, which were used for separate preparations of DNA,
RNA and protein.
For a histopathological assessment of each sample’s cellu-
lar composition, the three tissue sections were stained with
hematoxylin and eosin (H&E staining). Selected samples were
subjected to Masson trichrome staining (Sigma-Aldrich,
Munich, Germany). They were scanned with a ScanScope GL
system (Aperio Technologies, Vista) and visualised using the
accompanying software. For each tissue sample, different
pathologists evaluated independently the histology and esti-
mated the percentages of normal, tumour and stroma cells.
Immunohistochemistry
Morphological evaluation of the H&E-stained tissues was
supplemented by immunohistochemical staining of the major
non-malignant compartments. Acinar, stromal and immune
cells were visualised with antibodies targeting amylase-A2-
alpha (AMY2A; sheep IgG, abcam #ab18934; Abcam, Cam-
ridge, UK), smooth muscle actin alpha (SMACTA2; mIgG2a,
DAKO #M 0851; Dako, Hamburg, Germany) and common
leucocyte antigen CD45 (mIgG1, DAKO #N1514), respec-
tively. Formalin-ﬁxed, parafﬁn-embedded (FFPE) sections
were stained according to a standard protocol.13 In brief, 4
mm-thick sections were heated to 968C in citrate buffer (pH
6) for 30 min to retrieve the antigens. They were blocked
with methanol containing 3% H2O2 and universal blocking
reagent (BioGenex, San Ramon) and exposed to primary
antibodies at 48C overnight. After washing in TBS with
0.05% Tween-20, slides were exposed for 45 min to anti-
sheep (KPL #5220–0372) or anti-mouse (DAKO #K400) sec-
ondary antibodies labelled with horseradish peroxidase, then
incubated with DAB reagent (Dako) for 1 hr and counter-
stained with hematoxylin. The images were recorded using a
light microscope equipped with the AxioVision software
(Zeiss, Oberkochen, Germany).
DNA methylation profiling
DNA was isolated with the AllPrep Isolation kit (Qiagen, Hil-
den, Germany), following the manufacturer’s protocol. We
performed on 12 normal and 12 PDAC samples the Inﬁnium
What’s new?
To date, relatively few RNA expression data are available on pancreatic tumour types other than pancreatic ductal adenocarci-
noma (PDAC) or peritumoral tissues. Here, the authors found that transcriptionally, peritumoral tissues of PDAC behave much
like the tumours, although resembling normal tissue in cell composition. In contrast, transcription in the environment of cystic
pancreatic tumours is basically identical to that of normal tissue, suggesting an effect of peritumoral tissues on the strong
pathogenic difference between PDAC and cystic tumours. At the functional level, autophagy-related genes are uniquely
changed in PDAC and its peritumoral tissue, with their expression variation predicting patient survival.
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Human Methylation 450 BeadChip assay of Illumina (San
Diego), which interrogates 485,000 methylation sites across
the human genome, using 1 mg of DNA per sample.
Bisulﬁte-converted DNA (EpiTect Bisulﬁte kit; Qiagen) acted
as template for whole-genome ampliﬁcation, enzymatic diges-
tion, followed by a DNA clean-up process and hybridisation
to the BeadChip. The samples were washed and scanned
with the BeadArray Reader (Illumina). From the signal inten-
sities, the degree of DNA methylation was analysed using the
Illumina Bead studio software.
Transcriptional profiling
For RNA isolation, the frozen tissue slices were submerged in
liquid nitrogen and gently ground with a polypropylene
micropestle (Eppendorf, Hamburg, Germany) in a 2 ml
Eppendorf tube. Total RNA was isolated with the AllPrep
Isolation kit (Qiagen), following the manufacturer’s protocol.
RNA integrity was evaluated using an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto). Only samples with
an RNA integrity number of at least seven were used for fur-
ther analyses. The total RNA prepared from individual sam-
ples was analysed on Sentrix Human-6v3 Whole Genome
Expression BeadChips (Sentrix Human WG-6; Illumina). To
synthesize ﬁrst and second strand cDNA and for amplifying
biotinylated cRNA, the Illumina Totalprep RNA Ampliﬁca-
tion kit was used. Hybridisation to the BeadChip was per-
formed according to the manufacturer’s instructions.
Subsequently, the arrays were scanned with a BeadArray
Reader (Illumina).
Data analysis
Preprocessing and quality control. Raw data were exported
from the Illumina Beadstudio software and processed by R/
Bioconductor scripts.14 The data was quantile normalised
and log2 transformed. Distribution and quality of the
expression data was performed using principle component
analysis and hierarchical clustering. The raw and normalised
data are accessible at the public database ArrayExpress
(DNA methylation proﬁling ID: E-MTAB-3855; password
“pyzqdbii”; transcriptional proﬁling ID: E-MTAB-1791; pass-
word: “rpqqrysi”).
Differential expression analysis. Signiﬁcant differentially
expressed transcript features were detected using the LIMMA
package of R/Bioconductor15 by pairwise comparisons of the
groups (e.g., PDAC vs. normal; chronic pancreatitis vs. nor-
mal; etc.). The resulting p-values were adjusted for multiple
testing using Benjamini-Hochberg’s false discovery rate
(FDR) method; features with a FDR< 0.01 and an absolute
log2-fold change |log2FC|>0.5 were considered signiﬁcant.
For a functional enrichment analysis, the Ingenuity PA soft-
ware tool (Ingenuity Systems, http://www.ingenuity.com) was
applied.
Survival analysis. Cox’s proportional hazards models were
used for exploring the relationship between the survival of a
patient and several explanatory variables, including pheno-
typic parameters and gene expression. Analysis was per-
formed on PDAC patients utilising the survival package of R/
Bioconductor. This analysis returns statistical signiﬁcance of
prognostic variables included into the model and allowed to
estimate the risk of death for individuals. A positive regres-
sion coefﬁcient (or log hazard ratio) for an explanatory vari-
able at high signiﬁcance level means that the hazard is
higher, and thus the prognosis is worse. Conversely, a nega-
tive regression coefﬁcient implies a better prognosis for
patients. We started with checking the effect of phenotypical
parameters: age, gender, cancer stage, smoking and alcohol
intake. Then the effect of gene expression was investigated
for each gene independently and FDR-adjusted p-values of a
Wald test were assigned to them.
Signature selection amongst autophagy-related genes. We
used the intersection among signiﬁcant genes in order to
identify autophagy-related genes, which can be used as
prognostic signature for PDAC. Before analysis, we summa-
rized microarray features to the gene level in order to
merge data from features targeting the same gene. Genes
were selected that were differentially expressed, linked to
survival by Cox regression (FDR< 0.01) and annotated as
autophagy-related genes in relevant literature and data-
bases16,17 (see also Supporting Information Table S1). In
order to transform expression intensity values of genes to a
single value, we used an approach presented before.18 Gene
expression values were median-centred, and expression val-
ues of genes with a negative Cox’s coefﬁcient were inverted
by multiplication by minus one in order to account for a
survival effect. Then, gene expression of each patient was
summed up forming a single score. Predictive power of the
signature was characterised using support vector machine
(SVM) as a classiﬁer. Cancer patients were divided into two
groups with “good” and “poor” prognosis based on their
survival in relation to median survival time of the
patients.19 Gene expression was used as input to a support
vector machine classiﬁcation; output was considered as a
binary signal for “good” or “poor” survival. During perfor-
mance testing, 80% of the patients were randomly selected
as a training set, keeping a correct proportion of good/poor
prognosis patients. This operation was repeated 1,000 times
in order to characterise conﬁdence intervals for accuracy
(ratio between numbers of correctly classiﬁed patients to
total number).
Pathway analysis of differentially expressed genes
Differentially expressed transcripts were mapped onto a
molecular network developed from information contained in
the Ingenuity knowledge base (Ingenuity Systems). Gene net-
works were generated based on their interconnectivity. Inge-
nuity Pathway Analysis ranks the resulting networks by
calculating a signiﬁcance score corresponding to the negative
log of p values. Furthermore, pathway core analysis identiﬁed
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the pre-speciﬁed canonical pathways that were most over-
represented in the data set. Fisher’s exact test was used to
calculate a p values for the association between the genes in
the data set and the canonical pathway or network.
RT-PCR confirmation
For RT-PCR, 1 lg total RNA of 20 samples per group (nor-
mal pancreas, PDAC and PDAC macro-environment) was
reverse-transcribed using the ProtoScript M-MuLV First
Strand cDNA Kit (New England Biolabs, Frankfurt, Ger-
many). Quantitative RT-PCR was performed in triplicate on
a LightCycler 480 (Roche Diagnostics, Mannheim, Germany)
with a pre-ampliﬁcation incubation of 958C for 10 min, fol-
lowed by 45 cycles of 958C for 10 sec and 558C for 30 sec.
The following molecules of the QuantiTect Primer Assays
(Qiagen) were used as primers: Hs_ACTB_1_SG,
Hs_PKM_1_SG, Hs_PLK4_1_SG, Hs_PRAF2_1_SG and
Hs_BUD13_1_SG. BUD13 was used as reference gene as it
showed constant mRNA expression in all 452 analysed pan-
creatic tissue samples and an adequate expression level. Data
were analysed using the LightCycler software (Roche).
Results
Comparison of transcriptional variations in different
tissue types
The study was performed on initially 1,004 pancreatic tissue
samples collected at three clinics in Heidelberg (Germany),
Liverpool (UK) and Verona (Italy) by resection from cancer
patients or donors who had pancreatic tissue removed for
reasons other than cancer. Molecular sample analysis was
performed in one central laboratory, following the same
protocols throughout. From each sample, three tissue slices
were evaluated by experienced pathologists in a central
pathology review prior to further analysis, estimating the
percentages of normal, tumour and stromal cells as well as
the degree of inﬂammatory inﬁltration. In total, 452 RNA
preparations met our quality standards (see Methods sec-
tion) and were included in the transcriptional proﬁling anal-
ysis. The quality assessment was done prior to any
subsequent analysis, thus purely based on RNA quality and
unbiased. The percentage of only about 45% good-quality
preparations is not surprising when dealing with clinical
material, and particularly with pancreas samples, which con-
tain a very high level of RNases. Many samples of lower
quality could have been used on the microarrays. However,
the signiﬁcantly higher background combined with weaker
signal intensities that results from degraded RNA would
have made the data far less accurate and reproducible and
could not have been offset by the then larger number of
samples in the overall analysis.
The distribution of the analysed samples was studied by a
principle component analysis (Fig. 1), already indicating dif-
ferences between the tissue types. In addition, few apparent
discrepancies of the histological and molecular stratiﬁcation
could be observed. Of particular interest were samples of
non-tumorous tissue that had been located next to the actual
tumour. These peritumoral tissues had been in a distance of
about 1 to 10 mm from the tumour and did not exhibit any
tumour cell content in the histochemical analyses. They con-
sisted of parenchyma and stroma and are referred to as
“macro-environment” below. The 452 high-quality samples
represented 195 cases of PDAC, 30 cases of PDAC macro-
environment (N_PDAC), 24 cystic tumours (CT), 22 macro-
environmental tissues from next to cystic tumours (N_CT),
59 samples of chronic pancreatitis (CP), and 41 healthy pan-
creatic tissues from non-cancer patients (N). The subtypes of
the cystic tumours and the relevant macro-environments are
listed in Supporting Information Table S2. Other neoplasms,
for which RNA was isolated but ignored in the analysis
reported below, were 18 endocrine tumours, 2 macro-
environmental samples of endocrine tumours, 31 other pan-
creatic tumours, 15 related macro-environment tissues as well
as 15 tissues from the macro-environment of CP (N_CP).
Information about clinical patient parameters is given in
Table 1.
Many genes exhibited changes at the transcript level in
the various tissue types compared to samples from healthy
donors (Supporting Information Fig. S1; Supporting Informa-
tion Table S3). Also, a large number of changes were found
that were common between different tissues (Fig. 2). It is
noteworthy that this means a variation in the same direction
(up or down, respectively) as compared to the normal tissue
and not an increase in one and a decrease in the other tissue.
As a matter of fact, an analysis revealed that basically all
genes, which showed a signiﬁcant variation in two tissues,
were similarly regulated either up or down in both when
comparing N_PDAC, PDAC and cystic tumours (Fig. 2e).
This lack of inverse regulation suggests that functionally
Figure 1. Principle component analysis of the samples based on
their transcript profiles. The colour code of the tumour types is
given at the top. The plot shows a high degree of similarity of
PDAC and cystic tumours, indicates a distinct difference between
their macro-environments and highlights a similarity of the macro-
environments of cystic tumours and healthy tissues.
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similar cellular effects are triggered by these common tran-
scriptional changes.
Particularly interesting results were obtained from the
macro-environments of PDAC and cystic tumours, which
histologically showed a similar cell composition (Supporting
Information Figs. S2 and S3). To conﬁrm this further, we
also performed immunohistochemical analyses. Acinar, stro-
mal and immune cells were visualised in formalin-ﬁxed, par-
afﬁn-embedded sections with antibodies targeting amylase-
A2-alpha, smooth muscle actin alpha and CD45, respectively
(Supporting Information Fig. S4). Non-tumorous peritumoral
samples exhibited no abnormalities, such as acinar loss,
tumour cell invasion, stromal hyperplasia or inﬂammatory
inﬁltrates. Only two of the PDAC macro-environments
exhibited a GGT>GAT mutation of KRAS in codon 12; all
other samples had no KRAS mutations. Compared to the
transcript proﬁles obtained from normal tissue, a large num-
ber of genes were found differentially transcribed in PDAC
macro-environment, indicating that the phenotypically non-
tumorous appearance does not represent the molecular status
(Fig. 2a). In addition, there was a substantial overlap of 2,641
genes with the results obtained from PDAC, of which 1,997
were also changed in CP. At a transcriptional level, the
PDAC macro-environment and tissue of patients with CP
were similarly different to normal tissue. However, PDAC
macro-environment exhibited signiﬁcantly more molecular
resemblance with tumour tissue than with CP. For cystic
tumours, there was a rather different picture. The overlap
with the transcriptional pattern of CP was identical in num-
ber to the overlap of PDAC and CP (Fig. 2b). However, in
contrast to the PDAC result, the macro-environment of cystic
tumours behaved very similar to normal pancreatic tissue
with only 343 differentially transcribed genes as opposed to
2,909 genes in PDAC macro-environment. In a comparison
of the macro-environments of PDAC and cystic tumours
(Fig. 2c), only 45 differentially expressed transcripts were
found to be speciﬁc for the macro-environment of cystic
tumours. All this is also graphically represented in the princi-
ple component analysis (Fig. 1).
Variations that are specific to PDAC and its
macro-environment
Since PDAC represents the vast majority of clinical pancre-
atic cancer cases and has the worst prognosis, we focussed
our analysis on this tumour type. More than half of the
5,196 genes that exhibited signiﬁcant variations in PDAC
compared to healthy tissue were also differentially expressed
in PDAC macro-environment or CP tissues (Fig. 2a). The
1,997 regulated genes shared between the three tissue types
mostly represent changes that are associated with inﬂamma-
tion. The most overrepresented canonical pathways deﬁned
by these genes are relevant for immunological and inﬂamma-
tory response (Supporting Information Fig. S5). Next to the
shared transcript variations, there were (marker) genes that
exhibited expression changes that were unique to each tissue
type. The six most signiﬁcant biological functions associated
with the 2,373 unique PDAC expression markers are: cellular
growth and proliferation; cellular movement; cell death and
survival; cancer; cell cycle; as well as organismal injury and
abnormalities (Fig. 3). There were no over-represented func-
tions that are associated with inﬂammation. In contrast to
this, the 127 and 162 markers that were unique to the PDAC
macro-environment or CP, respectively, are genes over-
representing functions associated with both inﬂammation
and cancer. An analysis of the CT expression markers pro-
duced results rather similar to that of PDAC (Fig. 3).
Table 1. Clinical characteristics of patient cohort
N CP PDAC N_PDAC CT N_CT Others
No. of patients 41 58 195 30 24 22 82
Gender (male/female) 26/15 48/10 109/86 21/9 7/16 4/18 50/32
Age at surgery,
median (range)
46.0 (16–74) 47.1 (13–73) 63.4 (40–85) 60.8 (34–84) 62.0 (23–75) 57.1 (38–75) 55.7 (13–86)
Stage
0 n/a n/a – – – –
IA n/a n/a – – 2 – 1
IB n/a n/a 1 – 0 – 1
IIA n/a n/a 21 5 3 3 5
IIB n/a n/a 123 18 6 1 24
III n/a n/a 7 – – – 2
IV n/a n/a 17 2 1 – 4
Median survival-time
in months, (range)
n/a n/a 24.7 (1–159) 19.7 (1–65) 15.9 (1–36) 48.5 (1–141) 18.22 (1–54)
Details are listed of the clinical parameters of the patients from whom the 452 RNA-preparations were isolated and subsequently analysed. N:
healthy tissue; CP: chronic pancreatitis; PDAC: pancreatic ductal adenocarcinoma; N_PDAC: macro-environment of PDAC; CT: cystic tumour; N_CT:
macro-environment of cystic tumour; n/a: not applicable
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Of particular interest are the 644 regulated transcripts
shared between PDAC and its macro-environment but not
regulated in CP (Fig. 2a; Supporting Information Table S4).
The fact that the non-tumorous macro-environment tissue
exhibited a large number of variations, which are common
with PDAC only, suggests the possibility of a cancer ﬁeld
defect at the transcript level. A cancer ﬁeld defect is deﬁned
as a biological cancerisation process in which tissue in rela-
tively large areas beyond the actual tumour is exhibiting epi-
genetic changes similar to the ones of the actual tumour.11,12
Methylation changes are expected to result in variations at
the transcript level, too. To reveal the degree by which pro-
moter methylation may be responsible for the observed varia-
tions at the RNA level, we analysed the genomic DNA of 24
randomly selected samples, 12 each from healthy donors and
PDAC patients, from which we had also obtained mRNA
proﬁles. In the set of 644 transcripts shared by PDAC and its
macro-environment, 154 genes exhibited an inverse
correlation of promoter methylation and mRNA expression:
115 hyper-methylated promoters could be linked to down-
regulation of the mRNA level, 39 hypo-methylated promoters
coincided with transcripts that were present in higher abun-
dance. However, for the majority of genes, 490, there was no
such correlation of promoter DNA methylation and gene
expression. For 76 genes, there was even a concurrent
increase or decrease, respectively, of both methylation and
mRNA level.
Pathways and gene networks affected in the macro-
environment of PDAC
Transcripts showing signiﬁcant expression differences in the
macro-environment of PDAC as compared to healthy control
samples were submitted to a functional bioinformatics exami-
nation using Ingenuity pathways analysis. In this analysis,
one particular network of genes was identiﬁed. It consists of
73 directly linked genes (Supporting Information Fig. S7;
Figure 2. Tissue specificity of mRNA level variations. For each tissue type, the number of mRNAs is shown that were significantly differen-
tially expressed in comparison to normal pancreas tissue (N). The numbers in overlap regions stand for genes, regulated similarly in the rel-
evant tissues. (a) Results are presented for PDAC, the related macro-environment (N_PDAC) and chronic pancreatitis (CP), marked in red,
green and yellow, respectively. (b) The panel presents the same for cystic tumours (TC; brown), the related macro-environment (N_CT; blue)
and again chronic pancreatitis (CP; yellow). (c) The macro-environment of cystic tumours (N_CT) exhibited relatively few variations at the
mRNA level that were specific. (d) Presentation of the result of a comparison of all five data sets. (e) Correlation in the direction of variation
observed for N_PDAC versus N (top panel) or CT versus N (bottom panel), respectively, in comparison to PDAC versus N. Both axes repre-
sent the score shown above the panels, thus focussing on the most significant variations (shown in blue). Grey dots, mostly close to the
centroid, represent insignificant changes. All actual data is accessible in Supporting Information Table S3.
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Supporting Information Table S5). Many genes show a grad-
ual change of expression from healthy via CP to PDAC
macro-environment and ﬁnally PDAC. Two typical examples
are the chemokine receptor CXCR4 (chemokine (C-X-C
motif) receptor 4) and NUPR1 (nuclear protein transcrip-
tional regulator 1). CXCR4 is a prognostic marker in various
types of cancer and a biomarker of migrating pancreatic
cancer-initiating cells in mice.20 It was up-regulated com-
pared to normal tissue by a factor of 3.51 in CP, 4.38 in the
macro-environment and 6.68 in PDAC. NUPR1 interacts
with numerous partners to regulate cell cycle, apoptosis,
autophagy, chromatin accessibility, and transcription.
Reduced expression promotes pancreatic cancer develop-
ment.21 It was downregulated by 21.80 (CP), 22.10 (macro-
environment) and 22.41 (PDAC). Numerous genes within
the network are essential in Pancreatic Adenocarcinoma Sig-
nalling, as well as the Integrin-Linked Kinase (ILK) and
mTOR Signalling pathways. ILK is known to transmit
mechanical stimuli to the mammalian target of the mTOR
Signalling pathway. mTOR is an evolutionarily conserved
protein kinase that integrates both intracellular and extracel-
lular signals and serves as a central regulator of cell metabo-
lism, growth, proliferation, survival, and autophagy. The Akt/
mTOR pathway mediates oncogenesis and controls tumour
cell growth.22
Based on these ﬁndings, we took a closer look at these
pathways (Supporting Information Fig. S8). Interestingly, in
the Pancreatic Adenocarcinoma Signalling pathway, 35 of the
106 genes (33%) are annotated as relevant to autophagy. For
ILK/mTOR Signalling, the absolute number of autophagy-
related genes was even higher with 54 molecules out of 186,
although the percentage was slightly lower with 29%. The
considerable overrepresentation of autophagy-associated
genes suggested a strong link between autophagy and pancre-
atic cancer. This was corroborated by the overall number of
autophagy-related genes found to be regulated in PDAC. Of
the genes that were assayed in the transcriptional proﬁling
experiments, 512 are annotated to be associated with auto-
phagy processes according to two public autophagy data-
bases.16,17 Of these, 88 genes were regulated in CP compared
to normal tissue. In the macro-environment, this number
increased to 108 genes, while 208 genes were regulated signif-
icantly in PDAC (Supporting Information Table S6). Given
the obvious importance of autophagy for pancreatic cancer
and the fact that about 40% of all autophagy-related genes
were signiﬁcantly regulated in PDAC or in the PDAC
macro-environment, we focussed further analyses on those
genes.
Autophagy-related genes in PDAC, cystic tumours and
macro-environment
In our data set, there were several autophagy-related genes
that are known markers for pancreatic cancer. Examples are
ATG3, ATG4A, ATG4B, ATG4C and ATG523 showing down-
regulation in PDAC and its macro-environment. Also the
ductal transcription factor HNF6 (ONECUT1) was less
Figure 3. Most overrepresented biological functions associated with the 2,373 and 2,619 unique marker genes of PDAC and CT, respec-
tively. Colour-coded maps of functional predictions resulting from an Ingenuity Pathway Analysis are shown. Each rectangle represents one
function. The intensity of the purple colour of a square is proportional to the number of genes that are associated with the respective func-
tion. The size of a square reflects the associated negative log10 of the assigned p values. Larger squares indicate a more significant overlap
between the genes perturbed in the dataset and the respective function. The top 10 biological functions were ordered in a bar blot accord-
ing to their significance by the negative log10 of the assigned p values. The complete lists can be found at Supporting Information Fig. 6.
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expressed. Such a reduction in HNF6 expression correlates
with human pancreatic cancer progression.24 HNF6 has also
been described as biomarker for acinar-to-ductal metaplasia25
suggesting that a phenotypic switch converting pancreatic
acinar cells to duct-like cells could lead to pancreatic intra-
epithelial neoplasia and eventually to invasive PDAC. Fur-
thermore, HNF6 is a transcription regulator of the UDP
glucuronosyltransferase (UGT) family members. Interestingly,
variations in the UGT genotype are associated with an altered
risk to pancreatic cancer.26 None of the above genes was reg-
ulated in the macro-environment of cystic tumours. As men-
tioned before, many mRNAs were signiﬁcantly differentially
transcribed in CP, PDAC macro-environment, PDAC and
cystic tumours, but not in the macro-environment of cystic
tumours (Fig. 2c). As cystic tumours are known to have a
much better prognosis than PDAC,27 factors that are regu-
lated in the macro-environment of PDAC but not in the
macro-environment of cystic tumours might be relevant for
the much more aggressive nature of PDAC.
Autophagy-related prognostic markers
Given the apparent importance of autophagy-related genes as
speciﬁc markers of PDAC and its macro-environment, we
wondered whether they could act as a clinically relevant sur-
rogate for disease and have prognostic signiﬁcance. To inves-
tigate this, the relationship was explored between patient
survival and several explanatory variables. First, a set of uni-
variable survival analyses was performed to address the
potential inﬂuence of the factors age, gender, tumour stage,
treatment, smoking, and alcohol consumption. Only tumour
stage showed a signiﬁcant linkage to survival (Wald p values of
0.0013). More speciﬁcally, we observed the difference between
two groups, early stage (S2) and late stage (S3, S4) patients,
with a Cox regression coefﬁcient or log hazard ratio of 1.02
60.51 (95% conﬁdence interval). Then, the effect of gene
expression was investigated for each gene individually. In total,
35 autophagy-related transcripts were differentially transcribed
in PDAC and statistically linked to survival time (Supporting
Information Table S7). Eighteen genes were regulated in both
PDAC and its macro-environment (Table 2). The top-
candidates were PRAF2, PLK4, ACTB and PKM2. The tran-
script levels were conﬁrmed by qRT-PCR, ﬁtting to the micro-
array data in all cases (Supporting Information Fig. S9).
Interestingly, neither PRAF2 nor PLK4 had been connected to
PDAC so far. With respect to prognosis, the expression of the
two genes corresponded well with survival time and matched
the performance of hypoxia-inducible factor 1 alpha (HIF1A;
Fig. 4), whose change in expression has been shown to have a
strong impact on the prognosis of patients with PDAC.28
Based on the prognostic value of individual genes and by
cross-referencing this with the list of autophagy-related genes
that are differentially expressed in PDAC and its macro-
environment, we identiﬁed the most-informative signature,
which consists of 15 genes: ACTB, ANTXR1, CAMK1G,
DLG4, DNAJB9, EIF2AK3, ITPR1, MPDZ, MYO5C, NLE1,
P4HB, PKM2, PLK4, PRAF2 and WDFY2 (Supporting
Table 2. Result of a Cox regression of 18 autophagy transcripts statistically linked to survival time
Gene Cox Coeff. Cox FDR PDAC log2FC PDAC FDR N_PDAC log2FC N_PDAC FDR
ACTB 1.087 0.0023 1.298 0.000 0.768 0.000
ANTXR1 0.601 0.0088 1.373 0.000 0.843 0.000
CAMK1G 20.410 0.0008 1.140 0.000 1.015 0.001
DLG4 0.570 0.0001 0.761 0.000 0.902 0.000
DNAJB9 20.598 0.0069 21.300 0.000 20.904 0.000
EIF2AK3 0.846 0.0014 20.715 0.000 20.501 0.001
ITPR1 20.704 0.0017 0.741 0.000 0.816 0.000
MAP2K7 0.697 0.0179 20.901 0.000 20.608 0.000
MPDZ 20.685 0.0038 0.613 0.000 0.729 0.000
MYO5C 20.407 0.0036 20.818 0.000 20.780 0.001
NLE1 1.153 0.0050 20.728 0.000 20.532 0.000
P4HB 0.550 0.0057 21.079 0.000 20.592 0.003
PKM2 0.617 0.0004 1.475 0.000 0.702 0.000
PLK4 20.633 0.0034 0.991 0.000 0.529 0.000
PRAF2 1.068 0.0000 0.588 0.000 0.595 0.000
SH3GLB2 20.550 0.0198 20.726 0.000 20.713 0.000
VIM 0.421 0.0166 0.846 0.000 0.865 0.000
WDFY2 20.822 0.0052 21.192 0.000 20.915 0.000
A positive coefficient indicates a worse prognosis, a negative coefficient a protective effect. In addition, the regulation in PDAC and PDAC macro-
environment (N_PDAC) as compared to healthy tissue is shown. FRD: false discovery rate; log2FC: logarithm of fold change
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Information Fig. S10). Expression of these genes was com-
bined into a single score as described in the Methods section.
As a result, the score showed a strong statistical linkage to sur-
vival in a Cox regression model (Wald p values5 7 3 10214,
Cox coefﬁcient5 0.11 60.03). We observed a statistical link
between the calculated score and tumour stage (ANOVA p val-
ues of 0.013). Next, we classiﬁed patients by a support vector
machine as described in the Methods section: our classiﬁer dis-
criminated “good” and “poor” prognosis patients. As a basis,
they were divided into two groups based on their survival in
relation to the median survival time. The classiﬁcation was per-
formed 1,000 times using cross-validation approach and
resulted in an average accuracy of 82.6% 60.1% on training
data and 65.4% 60.5% on test data. The discriminating power
of the signature is shown in a Kaplan–Meier plot (Fig. 5), indi-
cating the substantial difference in survival between the
patients with low and high score calculated on that signature.
Discussion
We performed transcriptional proﬁling on various types of pan-
creatic tissue samples, focussing particularly on changes in
tissues that were located next to actual tumours. Comparison of
the expression data documented that PDAC and cystic tumours
are not that different at the transcriptional level, even though
892 and 516 genes, respectively, had expression patterns that
were unique to either tumour type. However, variation in 4,179
genes was in common. In addition, both tumour types shared a
rather similar set of transcriptional variations with CP tissues,
indicating the substantial contribution of inﬂammatory aspects
that are relevant for tumour pathology. The most signiﬁcant dif-
ference between PDAC and cystic tumours was actually found in
their surrounding, non-tumorous tissues. Histologically, they
exhibited a similar cell composition. However, while the PDAC
macro-environment behaved in part like the actual tumour, the
macro-environment of cystic tumours was transcriptionally
nearly identical to normal pancreas tissue. This suggests that
major differences between cystic tumours and PDAC may not
be solely intrinsic to the actual tumours, but could be triggered
indirectly by the way tumours inﬂuence or are inﬂuenced by
their wider cellular environment.
Assuming that a ﬁeld defect—an inﬂuence of the tumour
on the adjacent tissue11,12—could be responsible for the large
Figure 4. Linkage of gene expression levels in PDAC and patient survival time. Four typical Kaplan–Meyer curves with 95% confidence (dot-
ted lines) are shown. An increase in expression of PRAF2 is linked to poor survival, whereas stronger PLK4 expression predicts better sur-
vival. In the third panel, the result is shown for the established prognostic marker HIF1A, which is linked to poor survival. The expression
of ABL1 is not correlated to survival time at all and shown as a reference. The p-values shown are based on a Cox regression of continuous
log2 gene expression.
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number of genes, which were identically regulated in PDAC
and its macro-environment, and that it may be resulting
from DNA methylation processes, which have been impli-
cated in ﬁeld defects, we studied how the degree of promoter
methylation correlated with the transcriptional variations.
Surprisingly, the degree of inverse correlation—hyper-
methylation and low expression, hypo-methylation and high
expression—was rather low overall. One possible explanation
for this observation could be the presence of processes other
than DNA methylation, which regulate transcription. Any
such mechanism must be rather efﬁcient in transporting the
information, since the effect could be detected over distances
of several millimetres. MicroRNA transport in cellular
vesicles, such as exosomes, and absorption by recipient cells
has been shown to have such effects.29 In the intracellular
space, one would expect a gradient in the concentration of
exosomes radiated by tumours and a related gradient in the
degree of cellular transcriptional variations. The actual dis-
tance of the macro-environmental samples analysed in this
study was inadequately annotated so as to identify such an
effect.
Alternatively, it could be that only very few genes and
their methylation may be initiating the ﬁeld defect. Gene
NR5A2 (encoding the nuclear receptor subfamily 5, group A,
member 2) was found to be one of the genes, which was
both hyper-methylated and down-regulated in PDAC and
PDAC macro-environment. NR5A2 had not been described
as a methylation marker of PDAC before. However, single
nucleotide polymorphisms in the vicinity of NR5A2 have
been linked through genome-wide association studies to the
risk of developing PDAC, suggesting a broader role of this
gene in pancreatic homeostasis and disease.30 It was shown
that NR5A2 heterozygosity correlates with pancreatic damage
in the progression of mutant KRAS-driven preneoplastic
lesions, suggesting that NR5A2 could contribute to PDAC
through its role in the recovery from pancreatitis-induced
damage.31 The gene might be an interesting candidate for
exploring a potential cancer ﬁeld defect in pancreatic cancer.
With respect to clinical utility, a ﬁeld defect in the non-
tumorous tissue and the identiﬁcation and validation of rele-
vant molecular variations at the RNA level or the degree of
DNA methylation could allow the establishment of effective
disease biopsy markers, since they would also be present in a
wider distance to the actual tumour and therefore be easier
to collect.
One cannot rule out that other mechanisms than the ones
above might be responsible for the ﬁeld defect. For example,
surgeons and pathologists observe that peritumoral tissues in
patients with PDAC are apparently altered phenotypically,
while tissues adjacent to cystic or neuroendocrine tumours
often look quite normal. The mere degree of expansion of
PDAC and the resulting obstruction of the macro-
environment could be triggering transcriptional variations
that also occur in PDAC tissue but not in or around the
slowly growing cystic tumours, thus providing a simple
mechanical explanation for the differences. Further studies
are required to deﬁne the molecular processes in more detail.
Our ﬁndings particularly indicate the relevance of
autophagy-related transcripts in the macro-environment of
pancreatic tumours and their potential role as prognostic
markers. Autophagy is an evolutionarily conserved catabolic
process, by which a cell digests its own cytoplasmic content.
Autophagy is activated in reaction to multiple stress factors
during cancer progression, such as hypoxia and poor nutrient
supply32 and has an important role in tumour development.33
Overall, the dynamic role of autophagy in cancer appears to
be complex and context-dependent. On the one hand, it
could function as a tumour suppressor, whose inactivation
promotes tumorigenesis,34 on the other hand, it may act as a
pro-survival pathway that helps tumour cells to handle meta-
bolic stress and to resist chemotherapeutic agents.35 In pan-
creatic cancer, autophagy is required for tumour growth36
and mediates survival of pancreatic-tumour-initiating cells in
a hypoxic microenvironment.37 Inhibition of autophagy
reduced pancreatic cancer growth independent of the p53 sta-
tus.36 Furthermore, autophagy was shown to be essential for
oncogenic KRAS-induced malignant cell transformation.
There are several early-phase clinical trials in progress target-
ing the autophagic machinery, among them a study of
MEK1/2 and AKT inhibitors in patients with KRAS-driven
pancreatic tumours.38
Prognostic signiﬁcance of autophagy-related protein
expression in resected pancreatic ductal adenocarcinoma has
been described.39 The study reports about a correlation of the
expression of ﬁve proteins with disease prognosis and was
based on immunohistochemistry on 73 tumour tissue sec-
tions. Our analysis studied all genes and has a focus on the
variations that occur in the macro-environment of the
tumour. The regulation of several autophagy-associated genes
correlated with survival-time. Of special interest are the
Figure 5. Prognosis of patient survival. Kaplan–Meier curves were
calculated based on an expression signature in PDAC of the 15
genes named in the figure (Wald p values of Cox model57 3
10214). In blue, the survival of the patients with low score (below
median) is shown; the red line represents the result of the patients
with high score (above median). The dotted lines correspond to
95% confidence intervals.
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prognostic factors that were particularly regulated in pancre-
atic cancer and its macro-environment, such as PRAF2 and
PLK4, as these transcripts might be useful in distinguishing
inﬂamed versus oncogenically transformed regions of the
pancreas. PRAF2 (Prenylated Rab acceptor 1 domain family,
member 2) is a small transmembrane protein with a putative
role in transport from the endoplasmic reticulum to the
Golgi apparatus. It induces apoptotic cell death upon expres-
sion and is counteracted by Bcl-xL.40 It stimulates cell proli-
feration and migration and predicts poor prognosis in
neuroblastoma and glioma.41,42 In a genome-wide siRNA
screen aiming at the identiﬁcation of new genes involved in
autophagy, PRAF2 was found as a gene mediating auto-
phagy.43 PLK4 (Polo-like kinase 4) is a conserved upstream
regulator of centriole duplication. It is aberrantly expressed
in different tumour types,44 causing a loss of centrosome
numeral integrity, thereby promoting genomic instability.
PLK4 interacts with Cep63, which was shown to be degraded
in autophagy-controlled centrosome number variations.45
Recently, a cell line model of centrosome ampliﬁcation was
described, which exhibited elevated levels of autophagy upon
induced expression of PLK4.46 A drug discovery programme
identiﬁed a potent and selective small molecule inhibitor of
PLK4,47 which may have therapeutic implications for PDAC.
Already individual differentially expressed autophagy-
related transcripts allowed a disease prognosis that is equiva-
lent to markers reported before. By combining 15 autophagy-
related genes, we obtained a signature, which allowed an
even better classiﬁcation. Even though some transcripts
exhibited an only modestly differential expression in PDAC,
they documented a signiﬁcant prognostic power. These tran-
scripts may offer a means for a better prognosis after tumour
resection, although limitations apply for utilising actuarial
probabilities for a prediction of the actual survival of an indi-
vidual patient.48 However, the analysis highlights the impor-
tance of autophagy for tumour pathology and indicates that
this process is likely to be highly relevant for future treatment
strategies and monitoring of their success.
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